In addition, a new study further confirmed that the overexpression of CIP2A was a key contributory event of AKT phosphorylation in the correlation analysis of p-AKT and CIP2A in 220 clinical samples, and emphasized that the CIP2A-AKT axis is a promising therapeutic target for breast cancer (Luque et al., 2022). The gene discussed is CIP2A; the disease is breast carcinoma.